FindTrial
Sign In

Inhaled budesonide in neonatal respiratory distress syndrome: is it beneficial?

Inhaled budesonide in neonatal respiratory distress syndrome: is it beneficial?

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20201228003
Enrollment
Unknown
Registered
2020-12-28
Start date
2016-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal respiratory distress neonate &#44

Interventions

The studied neonates(120 neonates) were put into 2 groups: group 1(inhaled budesonide group=60 neonates)&#44
who had taken inhalation of corticosteroids (BUD 2mL &#44
0.25mg/ml suspension for nebulizer&#44
AstraZinca AB&#44
151 85 Södertälje&#45
Seweden) in addition to 2 ml of 0.9% saline through a face mask connected to O2 flowmeter(5L/min)&#44
daily for 5 days (2 times per day /12 hours) ,placebo is 2ml of distilled water
Experimental Drug,Placebo Comparator Other
inhaled budesonide supplementation,placebo

Sponsors

mohamed shawky elfarargy
Lead Sponsor
Ghada Alashmawy
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: neonates suffering from RDS

Exclusion criteria

Exclusion criteria: neonatal infections

Design outcomes

Primary

MeasureTime frame
respiratory distress at 5 days after end of the intervention(inhaled budesonide administration) ELISA method for measuring IL-8 in neonate with respiratory distress—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Egypt

Contacts

Public Contactmohamed elfarargy

Tanta University Hospital

farargy2009@hotmail.com+201005171750

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026